- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01116193
Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia (RV-405 LAL)
A Phase II, Multi-center, Open-label, Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Low-dose Dexamethasone in Patients With Refractory B Cell Lineage Acute Lymphoblastic Leukemia or in Relapse After 2 Lines of Treatment
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Clermont-Ferrand, France, 63003
- CHU de Clermont-Ferrand
-
Grenoble, France, 38000
- Hôpital Michallon
-
Lyon, France, 69003
- Hôpital Edouard Herriot
-
St Priest en Jarez, France, 42271
- Institut de Cancerologie de La Loire
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Documented B-cell lineage acute lymphoblastic leukemia (non-Philadelphia positive chromosome), which under WHO guidelines is now referred to as precursor B-lymphoblastic leukemia/lymphoma.
- Must have failed to at least two treatment regimens for B lineage ALL or must be refractory to chemotherapy. The inclusion of a patient with Ph+ ALL can be possible after contacting the principal investigator in presence of a T315I mutation and absence of investigational trial targeting this abnormality.
- Performance status of ≤ 2 by Eastern Cooperative Oncology Group (ECOG) criteria.
- Any age ≥ 18 years is allowed.
- Life expectancy of at least 3 months.
- Adequate liver function (aspartate transaminase [AST] and/or alanine transaminase [ALT] not > 3 times upper limits of normal).
- Adequate kidney function (calculated creatinine clearance > 50 ml/min).
- Signed informed consent prior to start of any study-specific procedures.
- The patients refusing the preservation of their biological samples can however participate in the study.
All subjects must
- Agree to abstain from donating blood while taking study drug therapy and for one week following discontinuation of study drug therapy.
- Agree not to share study medication with another person and to return all unused study drug to the investigator
Female subjects of childbearing potential must :
- Understand that the study medication is expected to have a teratogenic risk
Agree to use, and be able to comply with, effective contraception without interruption, 4 weeks before starting study drug, throughout the entire duration of study drug therapy (including dose interruptions) and for 4 weeks after the end of study drug therapy, even if she has amenorrhoea. This applies unless the subject commits to absolute and continued abstinence confirmed on a monthly basis. The following are effective methods of contraception
- Implant
- Levonorgestrel-releasing intrauterine system (IUS)
- Medroxyprogesterone acetate depot
- Tubal sterilization
- Sexual intercourse with a vasectomised male partner only; vasectomy must be confirmed by two negative semen analyses
- Ovulation inhibitory progesterone-only pills (i.e., desogestrel)
- If not established on effective contraception, the female subject must be referred to an appropriately trained health care professional for contraceptive advice in order that contraception can be initiated
- Understand that even if she has amenorrhea, she must follow all the advice on effective contraception.
- Understand the potential consequences of pregnancy and the need to rapidly consult if there is a risk of pregnancy
- Agree to have a medically supervised pregnancy test with a minimum sensitivity of 25 mIU/mL on the day of the study visit or in the 3 days prior to the study visit once the subject has been on effective contraception for at least 4 weeks. This requirement also applies to women of childbearing potential who practice complete and continued abstinence. The test should ensure the subject is not pregnant when she starts treatment
- Agree to have a medically supervised pregnancy test every 4 weeks including 4 weeks after the end of study treatment, except in the case of confirmed tubal sterilization.
Criteria for women of non-childbearing potential
A female subject or a female partner of a male subject is considered to have childbearing potential unless she meets at least one of the following criteria:
- Age ≥ 50 years and naturally amenorrhoeic for ≥ 1 year (Amenorrhoea following cancer therapy does not rule out childbearing potential.)
- Premature ovarian failure confirmed by a specialist gynaecologist
- Previous bilateral salpingo-oophorectomy, or hysterectomy
- XY genotype, Turner syndrome, uterine agenesis.
Male subjects must
- Agree to use condoms throughout study drug therapy, during any dose interruption and for one week after cessation of study therapy if their partner is of childbearing potential and has no contraception.
- Agree not to donate semen during study drug therapy and for one week after end of study drug therapy.
Exclusion Criteria:
- Active serious infection not controlled by oral or intravenous antibiotics.
- Treatment with any investigational antileukemic agent or chemotherapy agent in at least 7 days prior to study entry and lack of full recovery from side effects due to prior therapy independent of when that therapy was given.
- Rapidly progressive disease with compromised organ function judged to be life-threatening by the Investigator.
- Patients with clinical evidence of active central nervous system (CNS) disease.
- Pregnant and/or lactating female.
- Patients with known human immunodeficiency virus (HIV) infection.
- Patients with known active hepatitis B and/or hepatitis C infection.
- Hypersensitive or intolerant to any component of the study drug formulation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Disease-Free survival (DFS)
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival
Time Frame: 2 years
|
2 years
|
Progression-free survival
Time Frame: 2 years
|
2 years
|
Time to response
Time Frame: 28 days
|
28 days
|
Duration of response
Time Frame: 2 years
|
2 years
|
To determine quality of life (QOL): European Organization for Research and Treatment of Cancer QOL questionnaire for patients with cancer (EORTC QLQ-C30)
Time Frame: All 28 days
|
All 28 days
|
Feasibility of stem cell transplantation (SCT), in case of response, after one or more cycles of lenalidomide plus dexamethasone therapy
Time Frame: all 28 days
|
all 28 days
|
Safety of lenalidomide plus dexamethasone: adverse events (type, frequency, severity of adverse events, and relationship of adverse events to study drug).
Time Frame: All 28 days
|
All 28 days
|
To assess the efficacy of lenalidomide plus low-dose dexamethasone: complete response (CR), complete response without platelets (CRp), partial response (PR), and overall response (CR + CRp + PR).
Time Frame: 1, 8, 15, and 22 of each 28-day cycle (4-weeks cycles) and after treatment, patients will be seen at least twice weekly until they attain a CR
|
1, 8, 15, and 22 of each 28-day cycle (4-weeks cycles) and after treatment, patients will be seen at least twice weekly until they attain a CR
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Emmanuelle Tavernier, MD, Institut de Cancerologie de La Loire
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Lymphoid
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Dexamethasone
- Lenalidomide
Other Study ID Numbers
- 2009-01b
- 2009-009372-13 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia, Lymphoid
-
University Hospital, BrestRecruitingChronic Lymphoid LeukaemiaFrance
-
Institut Paoli-CalmettesAix Marseille UniversitéUnknownLeukemia, Myeloid, Acute | Acute Lymphoid LeukemiaFrance
-
Great Ormond Street Hospital for Children NHS Foundation...Medical Research Council; UCL Great Ormond Street Institute of Child HealthRecruitingRelapsed/Refractory T-cell Acute Lymphoid LeukaemiaUnited Kingdom
-
University Hospital, LilleAssistance Publique - Hôpitaux de Paris; Hospices Civils de Lyon; Central Hospital... and other collaboratorsCompletedAcute Lymphoid Leukemia Relapse | Acute Lymphoid Leukemia Relapse After Bone Marrow TransplantFrance
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyActive, not recruitingAdvanced Lymphoid LeukemiaUnited States, United Kingdom, Japan, France, Spain
-
French Innovative Leukemia OrganisationRecruiting
-
University of PennsylvaniaChildren's Hospital of PhiladelphiaActive, not recruitingAcute Lymphoid LeukemiaUnited States
-
University Hospital, ToursRecruitingAcute Lymphoid Leukemia | Acute Myeloid Leukemia in ChildrenFrance
-
Dana-Farber Cancer InstituteAcetylon Pharmaceuticals IncorporatedActive, not recruitingRecurrent Chronic Lymphoid LeukemiaUnited States
-
University Hospital TuebingenGlaxoSmithKlineRecruitingChronic Lymphoid Leukemia in RelapseGermany
Clinical Trials on Lenalidomide plus dexamethasone
-
CelgeneCompletedMultiple MyelomaSpain, United Kingdom, Switzerland, Australia, Israel, Italy, Poland, France, Belgium, Ireland, Austria, Germany, Ukraine, Greece, Sweden
-
University of LeedsTakeda; Cancer Research UK; CelgeneRecruitingMultiple MyelomaUnited Kingdom
-
Austrian Forum Against CancerUnknownMultiple Myeloma Light Chain Induced Renal InsufficiencyAustria, Czech Republic
-
Universitätsklinikum Hamburg-EppendorfGemeinsamer Bundesausschuss (G-BA); Staburo GmbHRecruiting
-
Bristol-Myers SquibbCompletedMultiple MyelomaUnited States, France, Australia
-
University of Michigan Rogel Cancer CenterCelgene; Onyx Therapeutics, Inc.CompletedMultiple MyelomaUnited States
-
University of LeedsMerck Sharp & Dohme LLC; Celgene; AmgenUnknown
-
Gesellschaft fur Medizinische Innovation - Hamatologie...ClinAssess GmbHCompletedMultiple MyelomaGermany
-
European Myeloma NetworkSanofi; Amgen; EMN Research ItalyActive, not recruitingMultiple MyelomaCzechia, Germany, Greece, Italy, Netherlands, Norway, Spain
-
University Health Network, TorontoCompletedMultiple Myeloma | Renal FailureCanada